Synopsis: Poly Medicure Limited, India’s largest exporter of consumable medical devices, is expanding globally through innovation, acquisitions, and manufacturing scale-up. With presence in 125+ countries, strong R&D, and entry into high-end segments like cardiology and orthopaedics, the company aims to evolve from a consumables manufacturer into a global medical technology platform.
Poly Medicure Limited has today become the most prominent medical device company in India, particularly in the field of consumable medical devices. Over the past decade, the company has become the largest exporter of consumable medical devices from India. The company supplies medical devices to various medical institutions worldwide. The company has developed a strong platform for itself with over 225 medical devices in the field of medical devices, including 13 medical specialities.
The company has become prominent in the fields of infusion therapy, renal, cardiology, and critical care medical devices. Today, the medical devices of the company are distributed in over 125+ countries through its network of over 950 distributors. The company has established itself in the medical field, including the healthcare industries of Europe, America, and other developing countries. The company has established itself through its 15 manufacturing units located in five different countries.
The company’s focus on high-volume hospital consumables such as IV cannulas, catheters, and dialysis products has helped the company carve out a strong niche for itself in the global medical device market. The company is also the largest IV cannula manufacturer in the world.
Expansion Through Innovation and Acquisitions
Another major pillar of the company’s global expansion strategy has been innovation and product diversification. Poly Medicure has significantly increased its focus on research and development. The company has over 100 R&D professionals in India and Europe and more than 390 patents. The company has been able to launch over 30 new products per annum with a robust R&D pipeline of future devices.
The company is also moving up the technology curve by venturing into more lucrative segments of the industry, including cardiology and orthopaedics. In the past two years, Poly Medicure has launched drug-eluting stents in the Indian market and has started clinical trials in India and Europe, marking the company’s foray into the high-end cardiovascular market. The company is thereby leveraging the huge and growing market in the global medical technology industry.
Another major factor for the company’s global expansion has been acquisitions. Poly Medicure has made acquisitions in European countries of several medical device manufacturers, including Plan1Health, Pendracare, and Citieffe. These acquisitions have helped the company gain expertise and strengthen its presence in these countries.
Scaling Manufacturing and Global Distribution
As part of its strategy for the growing global footprint, Poly Medicure is investing in the expansion of its manufacturing infrastructure. The second manufacturing unit located at Haridwar has already become operational, and the company is developing another unit at Palwal in the state of Haryana, which is expected to become operational in FY27. The company is also developing units in the region of the upcoming airport at Greater Noida.
As part of the strategy for growth, Poly Medicure is also investing in the development of its product offerings. The company is developing various critical care medical devices, neonatal equipment, and cardiology products, in addition to developing orthopaedic trauma products targeting the global market, including the United States and Europe.
As part of its strategy for growth, Poly Medicure is developing itself into a global medical technology company rather than just being a consumables company. As the demand for medical technology continues to grow globally, the strategy for growth that the company is employing could play an important role in the growth story of the company in the years ahead.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
